ABSTRACT
Progression of today's world has been given setback due to the adversity of a novel, viral and deadly outbreak COVID 19, which raised the concerns of the scientists, researchers and health related officials about the inherent and adaptive immune system of the living body and its relation with healthy diet balanced with pharma foods. Choice of right food can help to build and boost adaptive immunity and pumpkin due to excellent profile of functional and nutraceutical constituents must be the part of both infected and non-infected person's daily diet. Vitamins, minerals, phenolic acids, essential oils, peptides, carotenoids and polysaccharides present in pumpkin could accommodate the prevailing deficiencies in the body to fought against the pathogens. Pumpkins are well equipped with nutraceuticals and functional ingredients therefore, consumption and processing of this remarkable fruit must be encouraged as pharma food due to its antihyperlipidemic, antiviral, anti-inflammatory, antihyperglycemic, immunomodulatory, antihypertensive, antimicrobial and antioxidant potential, and these pharmacological properties of pumpkin are directly or indirectly related to the COVID 19 outbreak. Utilization of pumpkin has a domain in the form of powders, extracts, isolates, and pumpkin incorporated food products. A wide range of healthy, nutritious and functional food products has been developed from pumpkin, which includes juice, soup, porridge, chips, biscuits, bread, cake, bar and noodles. In recent times some innovative and novel technologies have been applied to process and preserve pumpkin for its enhanced shelf life and bioaccessibility of nutrients. Need of healthy eating in current post COVID 19 period is very crucial for healthy population, and medicinal foods like pumpkin, and bioactive compounds present in this functional food could play a vital role in developing a healthy community around the globe.
ABSTRACT
Objectives: To assess the impact of lymphopenia on the COVID-19 disease outcome. Study Design: Retrospective study. Setting: ICU and Isolation Ward of Hayatabad Medical Complex, Peshawar. Period: July 2020 to Dec 2020. Material & Methods: Different parameters of CBC were performed using the five parts Sysmex differential hematology analyzer BS-1800. A total of 274 patients were included via non probability sampling. Relevant information's were recorded on a pre-designed performa prepared in accordance with the objectives of the study. Results: The absolute lymphocyte count was lower in patients who were admitted in ICU as compared to those in isolation ward (p-value 0.07). Likewise patients with severe lymphocytopenia (lymphocyte count less than 50x10*9/L) had a greater rate of mortality (p value 0.01). No significant difference in term of TLC and ANC was noted in survivor's vs non survivors groups in present study. Conclusion: Our study concludes that lymphopenia serves as a reliable and early prognostic factor in determining disease severity and mortality COVID-19. [ FROM AUTHOR] Copyright of Professional Medical Journal is the property of Professional Medical Journal and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)
ABSTRACT
People of all age groups have been affected worldwide during the coronavirus disease 2019 (COVID-19) pandemic. While the global efforts of researchers, clinicians, and scientists are underway, cases involving multiple systems with a wide range of presentations are on the horizon. As health organizations have started warnings about unusual manifestations of a Kawasaki disease (KD)-like inflammatory syndrome associated with COVID-19, some pediatric cardiologists noted that even classic cases are likely going undercounted. Here we report a case of a previously healthy eight-year-old Pakistani boy who presented with a four-day history of low-grade fever. The patient was admitted and diagnosed with COVID-19-associated atypical KD in the setting of fever for more than five days, maculopapular eruptions, and mild conjunctivitis. He screened positive for COVID-19 with an immunoglobulin G titer of 2.1 plus ruling out other childhood illnesses. He was managed with intravenous immunoglobulins and aspirin with gradual resolution of symptoms. His initial echocardiogram was unremarkable. He was discharged home on day six with a follow-up at two weeks.
ABSTRACT
The whole world is concerned about the pandemic of coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), due to fatality of this condition. This has become a public health emergency of international concern. No specific vaccine and medicine have proven effective in large-sized trials at this time. With the rapidly increasing number of positive cases and deaths, there is a dire need for effective treatments and an effective vaccine for prevention. An urgent unmet need led to the planning and opening of multiple drug development trials for treatment and vaccine development. In this article, we have summarized data on cell receptor interactions and data on prospects of new vaccines targeting the deoxyribonucleic acid (DNA), messenger ribonucleic acid (mRNA), and viral minigenes. We have tabulated the available data on various clinical trials testing various aspects of COVID-19 vaccines.